Unknown

Dataset Information

0

Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.

ABSTRACT: Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).

SUBMITTER: Zimmer AS 

PROVIDER: S-EPMC7270957 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in muri  ...[more]

Similar Datasets

Unknown Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
| S-EPMC10153633 | biostudies-literature
Unknown Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies.
| S-EPMC8230933 | biostudies-literature
Unknown Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases.
| S-EPMC9841677 | biostudies-literature
Unknown Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
| S-EPMC5899637 | biostudies-literature
Unknown Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.
| S-EPMC7035200 | biostudies-literature
Unknown Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.
| S-EPMC3461152 | biostudies-literature
Unknown Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.
| S-EPMC4100541 | biostudies-literature
Unknown Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review.
| S-EPMC7493232 | biostudies-literature
Unknown Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer.
| S-EPMC9601150 | biostudies-literature
Unknown Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases.
| S-EPMC11582691 | biostudies-literature